Calliditas Therapeutics AB represents a set of core values and a corporate philosophy that focus on innovation, commitment, and patient-centricity. The company is dedicated to developing and commercializing therapies for patients with rare diseases and other unmet medical needs. Calliditas Therapeutics AB believes in fostering a culture of excellence, collaboration, and integrity to deliver meaningful and transformative healthcare solutions. With a strong emphasis on research and development, the company aims to improve patients' quality of life and provide hope for those suffering from chronic diseases.

Calliditas Therapeutics AB is primarily present in several countries and regions worldwide. The company has a strong presence in the United States, where it operates through its subsidiary, Calliditas Therapeutics Inc. Additionally, Calliditas Therapeutics AB is actively engaged in Europe, with significant operations and market presence in countries like Sweden, Germany, France, and the United Kingdom. The company strives to expand its reach and establish a global footprint by establishing partnerships and collaborations in different geographies. Calliditas Therapeutics AB focuses on developing innovative therapies and improving patient outcomes, benefiting individuals in various countries and regions through its dedicated efforts.

Calliditas Therapeutics AB has achieved several significant milestones. The company successfully completed a Phase 3 clinical trial for Nefecon, an investigational treatment for IgA nephropathy. In addition, Calliditas Therapeutics AB received Breakthrough Therapy designation from the U.S. FDA for Nefecon, recognizing its potential to address an unmet medical need. The company also entered into collaboration agreements with key partners, including Everest Medicines and Deva Holding, to further develop and commercialize its products. Furthermore, Calliditas Therapeutics AB successfully listed on the Nasdaq Stockholm exchange, improving visibility in the market. These achievements demonstrate the company's commitment to advancing innovative therapies and expanding its global presence.

Calliditas Therapeutics AB, a renowned biopharmaceutical company, has a rich history and background. Founded in 2004 and headquartered in Stockholm, Sweden, Calliditas focuses on developing novel treatments for rare kidney diseases. The company combines scientific expertise and innovative research to improve patients' lives. Calliditas Therapeutics AB went public in 2017 and trades on the Nasdaq Stockholm under the ticker symbol CALTX. With a strong commitment to patient care and leveraging cutting-edge technologies, Calliditas Therapeutics AB continues to make significant strides in the field of kidney disease therapies.

The main competitors of Calliditas Therapeutics AB in the market include pharmaceutical companies such as Mallinckrodt, Advicenne, and Retrophin.

Calliditas Therapeutics AB is primarily active in the pharmaceutical industry. With a focus on developing and commercializing innovative treatments, Calliditas Therapeutics AB specializes in rare and orphan diseases. As a specialized biopharmaceutical company, Calliditas Therapeutics AB is dedicated to improving the quality of life for patients suffering from severe diseases.

The business model of Calliditas Therapeutics AB is focused on developing and commercializing novel treatments for rare kidney diseases. The company aims to address unmet medical needs by developing innovative therapies and providing improved outcomes for patients. Calliditas Therapeutics AB conducts extensive research and development to create effective and safe treatments, incorporating clinical trials to evaluate their efficacy. By partnering with healthcare professionals, institutions, and stakeholders, Calliditas Therapeutics AB seeks to maximize patient access to its products and contribute to the advancement of renal care.

Det Calliditas Therapeutics P/E-forhold er 70,04.

Calliditas Therapeutics KUV er 5,21.

AlleAktien Kvalitetsscore for Calliditas Therapeutics er 3/10.

Den forventede Calliditas Therapeutics omsætning er 2,12 mia. SEK.

Den forventede Calliditas Therapeutics indtjening er 157,55 mio. SEK.

Calliditas Therapeutics AB is a Swedish biotechnology company focused on the development of medications for the treatment of rare diseases. The company was founded in 2004 and is headquartered in Stockholm. Calliditas is developing new therapeutic approaches for patients suffering from autoimmune and kidney diseases. The business model of Calliditas is based on the discovery, development, and commercialization of innovative medications that meet high medical needs and can have a significant impact on patients' lives. Calliditas conducts intensive research and development projects aimed at developing innovative drugs and treatment approaches that enable fast and effective healing. The main products of Calliditas are Nefecon, a medication for the treatment of IgA nephropathy, an inflammatory kidney disease, and Baylis Medical, which provides medical technology for diagnosing and treating kidney diseases. Nefecon is an innovative medication based on a unique proprietary technology platform that is designed to slow down the progression of IgA nephropathy. IgA nephropathy is a rare autoimmune disease that attacks the kidneys and can lead to irreversible damage. Calliditas also operates an extensive development program for a range of autoimmune diseases such as PBC, AAV, and Primary Sclerosing Cholangitis (PSC). Calliditas' research work aims to develop innovative drugs that target fast and effective treatment of these conditions. The company relies on a clinical pipeline that offers a wide range of potential therapy options. Calliditas has demonstrated a strong commitment to collaborating with leading academic institutions and the pharmaceutical industry to promote innovative research and utilize new technology platforms for drug development. The company strives to identify and build strategic partnerships. In summary, Calliditas is a leading biotechnology company developing innovative medications for the treatment of autoimmune and kidney diseases. The company has a clinical pipeline that offers a wide range of potential therapy options and is dedicated to research and development of innovative treatment approaches. Calliditas has built strong business partnerships with leading institutions and the pharmaceutical industry. The company aims to lead the healthcare industry in terms of research and innovation and improve the lives of patients worldwide.

Calliditas Therapeutics udbetaler et udbytte på 0 SEK fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Calliditas Therapeutics, eller selskabet udbetaler ikke udbytte.

ISIN'en for Calliditas Therapeutics er SE0010441584.

WKN for Calliditas Therapeutics er A2JP36.

Tickeren for Calliditas Therapeutics er CALTX.ST.

I løbet af de sidste 12 måneder betalte Calliditas Therapeutics en dividende på . Dette svarer til et dividendeudbytte på omkring . For de kommende 12 måneder vil Calliditas Therapeutics sandsynligvis betale en dividende på 0 SEK.

Udbytteafkastet for Calliditas Therapeutics er i øjeblikket .

Calliditas Therapeutics betaler kvartalsvis udbytte. Dette uddeles i månederne .

Calliditas Therapeutics betalte udbytte hvert år i løbet af de sidste 0 år.

For de kommende 12 måneder forventes der dividender på 0 SEK. Dette svarer til et dividendeafkast på 0 %.

Calliditas Therapeutics bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Calliditas Therapeutics fra den 8.7.2024 på 0 SEK, skulle du have haft aktien i din portefølje før ex-datoen den 8.7.2024.

Udbetalingen af det sidste udbytte blev foretaget den 8.7.2024.

I løbet af 2023 udbetalte Calliditas Therapeutics 0 SEK i form af dividender.

Udbytterne fra Calliditas Therapeutics udbetales i SEK.